Multiple Ascending Dose (MAD) Study of IMT-002 in HLA-DQ8-positive Type 1 Diabetes

Type1 Diabetes Clinical Trial

Official title:

A Phase 1b, Randomized, Single-blind, Placebo-controlled, Multiple Ascending Dose (MAD) Study to Assess the Steady-State Pharmacokinetics and DQ8 Blocking Efficacy of Orally Administered IMT-002 in Patients With Type 1 Diabetes and HLA-DQ8

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04625595
• Other study ID #: IMT-002-0102
• Status: Completed
• Phase: Phase 1
• Start date: November 9, 2020
• Est. completion date: July 31, 2021

Study information

• Verified date: June 2021
• Source: Immunomolecular Therapeutics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is designed to characterize the safety, steady-state pharmacokinetics (PK) of IMT-002, and will serve as a dose range identification for the pharmacodynamic effect of blocking self-antigen presentation in adults with type 1 diabetes (T1D) having the human leukocyte antigen (HLA)-DQ8 gene.

Description:

This is a randomized, single-blind, placebo-controlled study that will include 4 ascending dose cohorts: 350 mg twice daily (BID), 1050 mg once daily (QD), 700 mg BID, and 1050 mg BID. Subjects will undergo prescreening for genetic typing and then screening procedures up to 28 days prior to the first dose to determine eligibility. T1D adults between 18 and 45 years of age, inclusive, who are positive for at least one gene encoding for HLA-DQ8 (DQA1*0301, DQB1*0302) will be enrolled. Each cohort will include 6 subjects on active drug, and the study will include 6 subjects total on placebo. Each cohort will participate in a 2-week dosing period. Enrollment of the cohorts will be sequentially staggered such that initial safety data after the first four subjects assigned to active treatment complete one week of treatment in each cohort will be reviewed before the next ascending dose cohort is enrolled. The safety reviews will include cumulative safety data for all subjects to that point. Subjects will have 5 scheduled clinic visits: screening, first day of dosing, 1 week after dosing begins, 2 weeks after dosing begins (end of treatment), and 1 week following the final dose. Subjects will self-administer study drug on non-clinic treatment days. Safety assessments will be conducted at all study visits. Insulin use (dose and frequency) will be monitored. Pharmacokinetic (PK) assessments will be evaluated at every visit during the treatment period to characterize the following: single dose PK, trough PK and steady PK. Pharmacodynamic (PD) and immunological assessments will be evaluated before, during and after treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: July 31, 2021
• Est. primary completion date: May 11, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

1. Signed the ICF as described in Appendix 3 which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

2. Man or woman, 18 to 45 years of age inclusive at the time of signing the ICF.

3. Has received a diagnosis of T1D according to the criteria from the American Diabetes Association.

4. Positive for at least one gene encoding for HLA-DQ8 (DQB*0302).

5. If male, and of reproductive potential, willing to use medically acceptable birth control (Appendix 5), unless the female partner is postmenopausal or surgically sterile, until study completion and for at least 30 days after the last dose of study treatment and refrain from donating sperm during this period.

6. If female: (a) surgically sterile or (b) postmenopausal or (c) if of reproductive potential, willing to use medically acceptable birth control (eg, female hormonal contraception, barrier methods or sterilization (Appendix 5) until study completion and for at least 30 days (one menstrual cycle).

Exclusion Criteria:

1. Inability or unwillingness of a subject to give written informed consent or comply with the study protocol.

2. No HLA-DQ8 gene (DQB*03:02).

3. Any of the following hematologic abnormalities at the time of screening, confirmed by

repeat tests:

1. Leukopenia (<3,000 leukocytes/µL)

2. Neutropenia (<1,500 neutrophils/µL)

3. Thrombocytopenia (<125,000 platelets/µL)

4. Hemoglobin less than 10 g/dl

4. Evidence of liver dysfunction, with ALT > 2.5 times the upper limit of normal (ULN) or AST >3.0 times ULN persistent for 1 week or greater.

5. Evidence of renal insufficiency as indicated by serum creatinine of >1.5 times ULN, confirmed by a repeat test.

6. Clinically significant abnormal physical examination, vital signs, or 12-lead ECG at screening as deemed appropriate by the investigator.

7. Has a history of or current clinically significant medical illness including, but not limited to, cardiac arrhythmias or other cardiac disease; significant pulmonary disease; neurologic or psychiatric disease; infection; or any other illness that the investigator considers should exclude the subject or that could interfere with the interpretation of the study results.

8. Body mass index (BMI) > 32 kg/m2.

9. Unstable blood sugar control defined as one or more episodes of severe hypoglycemia (defined as hypoglycemia that required the assistance of another person) within the last 30 days.

10. Use of a treatment that is known to cause a significant, ongoing change in the course of T1D or immunologic status, within 4 weeks prior to participation; this includes high-dose inhaled, extensive topical or systemic glucocorticoids.

11. History of any organ transplant, including islet cell transplant.

12. Pregnant or anticipates pregnancy during the 2-week study period or within 30 days following the last dose of study drug.

13. Use of investigational drugs within 90 days of participation.

14. Currently taking methyldopa (Aldomet) at the time of randomization or taken within the past 3 months.

15. Currently taking ferrous sulfate or ferrous gluconate, which are indicated for the treatment of anemia (hematological disease), or taken within the past 30 days.

16. Unable to avoid medications that affect stomach pH, such as proton pump inhibitors or histamine H2 receptor blockers.

17. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the Investigator, may pose additional risks from participation in the study, may interfere with the subject's ability to comply with study requirements, or that may impact the quality or interpretation of the data obtained from the study.

18. Has a history of the human immunodeficiency virus (HIV) antibody positive, or tests positive for HIV; has a history of hepatitis B surface antigen (HBsAg) or hepatitis C antibody (anti-HCV) positive, or another clinically active liver disease, or tests positive for HBsAg or anti-HCV at Screening.

19. Has a known psychiatric or substance abuse disorder that would interfere with the subject's ability to cooperate with the requirements of the study.

20. Has preplanned surgery or procedures that would interfere with the conduct of the study.

21. Is an employee of the Investigator or study site, with direct involvement in the proposed study or other studies under the direction of that Investigator or study site, as well as family members of the employees or the Investigator.

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 1
• Type1 Diabetes

Intervention

Drug:
• 350mg BID (700mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule
Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily
• 700mg BID (1400mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule
Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily
• 1050mg QD (1050mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule
Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily
• 1050mg BID (2100mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule
Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily

Locations

Country	Name	City	State
United States	Barbara Davis Center	Aurora	Colorado
United States	Prosciento, Inc.	Chula Vista	California
United States	Rainier Clinical Research Center	Renton	Washington

Sponsors (2)

Lead Sponsor	Collaborator
Immunomolecular Therapeutics, Inc.	WCCT Global

Country where clinical trial is conducted

United States, 

References & Publications (5)

Au WY, Dring LG, Grahame-Smith DG, Isaac P, Williams RT. The metabolism of 14 C-labelled -methyldopa in normal and hypertensive human subjects. Biochem J. 1972 Aug;129(1):1-10. — View Citation

GILLESPIE L Jr, OATES JA, CROUT JR, SJOERDSMA A. Clinical and chemical studies with alpha-methyl-dopa in patients with hypertension. Circulation. 1962 Feb;25:281-91. — View Citation

Ostrov DA, Alkanani A, McDaniel KA, Case S, Baschal EE, Pyle L, Ellis S, Pöllinger B, Seidl KJ, Shah VN, Garg SK, Atkinson MA, Gottlieb PA, Michels AW. Methyldopa blocks MHC class II binding to disease-specific antigens in autoimmune diabetes. J Clin Invest. 2018 May 1;128(5):1888-1902. doi: 10.1172/JCI97739. Epub 2018 Apr 3. — View Citation

Ostrov DA, Gottlieb PA, Michels AW. Rationally designed small molecules to prevent type 1 diabetes. Curr Opin Endocrinol Diabetes Obes. 2019 Apr;26(2):90-95. doi: 10.1097/MED.0000000000000470. Review. — View Citation

SJOERDSMA A, VENDSALU A, ENGELMAN K. STUDIES ON THE METABOLISM AND MECHANISM OF ACTION OF METHYLDOPA. Circulation. 1963 Oct;28:492-502. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of adverse events (AEs) and serious adverse events (SAEs)	Frequency tabulated as number of participants with adverse and serious adverse events (AEs)	Treatment and follow-up period, Day 21
Primary	Change from baseline in electrocardiogram (ECG)	Single 12-lead ECG will be measured in a supine position after 5 minutes rest and measure QRS, QT, and QTc intervals	Day 1, Day 7, Day 14 and Day 21
Primary	Change in total daily insulin use	At each study visit, total daily insulin (ie, total insulin administered over the previous 24-hour period) will be entered in the Concomitant Medications CRF	Day 1, Day 7, Day 14 and Day 21
Secondary	Pharmacokinetic (PK) measurement in blood plasma, Cmax	Cmax, maximum plasma concentration during a dosing interval	Day 1, Day 7, Day 14
Secondary	Cytokine level from in vitro presentation of antigen by HLA-DQ8	Change from baseline of cytokine, interleukin-2, level produced in T-cell based in vitro assay of blood sample resulting from presentation of insulin or gluten peptide antigen by HLA-DQ8	Day 1, Day 7, Day 14 and Day 21